Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 16, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) under the US Deferred Performance Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume (ADSs) | Exchange |
|---|---|---|---|---|
| January 12, 2017 | American Depositary Shares (ADSs) | $39.01 | 266.485 | New York Stock Exchange (XNYS) |
| January 12, 2017 | American Depositary Shares (ADSs) | $39.01 | 358.523 | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document reports routine acquisitions of ADSs by executives following the re-investment of dividends paid on January 12, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of specific share transactions.
Key Facts for Investor Verification
- Transaction Nature: Both reported transactions were acquisitions of ADSs resulting from the automatic re-investment of dividends under the US Deferred Performance Plan, not open-market purchases.
- Executives Involved:
- Dr. M M Slaoui (Chairman, Global Vaccines) acquired 266.485 ADSs.
- Mr. D E Troy (SVP & General Counsel) acquired 358.523 ADSs.
- Transaction Price: All shares were acquired at a uniform price of $39.01 per ADS on the New York Stock Exchange.
- Reporting Limitation: This filing does not contain financial performance data; investors should refer to GSK's Form 20-F or quarterly reports for revenue and earnings information.